For treating melanoma, the US Food and Drug Administration (FDA) has approved several immunotherapy drugs that strengthen the immune system defense against melanoma cells and various targeted therapies to inhibit melanoma tumor growth [12], including the oncogenic B-Raf inhibitors vemurafenib [13] and dabrafenib [14] and the MEK inhibitor trametinib [15]. Here, MAP2K7 is linked to neoplasm.